Gainers
- Check-Cap (NASDAQ:CHEK) shares rose 225.1% to $2.42 during Monday's regular session. The market value of their outstanding shares is at $4.3 million.
- Helius Medical Tech (NASDAQ:HSDT) stock moved upwards by 162.71% to $19.86. The market value of their outstanding shares is at $8.1 million.
- NanoVibronix (NASDAQ:NAOV) stock rose 86.74% to $12.12. The company's market cap stands at $5.1 million.
- AVITA Medical (NASDAQ:RCEL) shares increased by 47.43% to $6.72. The market value of their outstanding shares is at $123.2 million.
- Monte Rosa Therapeutics (NASDAQ:GLUE) stock rose 34.51% to $6.47. The market value of their outstanding shares is at $297.0 million.
- C4 Therapeutics (NASDAQ:CCCC) shares moved upwards by 32.33% to $3.52. The company's market cap stands at $188.8 million.
Losers
- aTyr Pharma (NASDAQ:ATYR) shares decreased by 81.8% to $1.1 during Monday's regular session. The company's market cap stands at $590.8 million.
- Kindly MD (NASDAQ:NAKA) stock decreased by 49.83% to $1.4. The market value of their outstanding shares is at $1.0 billion.
- Cognition Therapeutics (NASDAQ:CGTX) stock fell 28.81% to $1.54. The company's market cap stands at $191.4 million.
- GlucoTrack (NASDAQ:GCTK) shares decreased by 26.73% to $7.76. The market value of their outstanding shares is at $9.5 million.
- Bionano Genomics (NASDAQ:BNGO) stock fell 24.1% to $2.94. The market value of their outstanding shares is at $18.1 million.
- SPRUCE BIOSCIENCES, (NASDAQ:SPRB) stock fell 21.96% to $9.68. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
BNGOBionano Genomics Inc
$1.970.93%
CCCCC4 Therapeutics Inc
$2.10-6.44%
CGTXCognition Therapeutics Inc
$1.74-5.14%
CHEKCheck-Cap Ltd
$1.945.43%
GCTKGlucoTrack Inc
$7.80-1.45%
GLUEMonte Rosa Therapeutics Inc
$9.99-0.50%
HSDTSolana Co
$15.374.56%
NAKAKindly MD Inc
$0.8442-2.97%
NAOVNanoVibronix Inc
$6.19-2.06%
RCELAVITA Medical Inc
$5.252.04%
SPRBSpruce Biosciences Inc
$172.93-0.39%
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.